Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Viking Thera
(NQ:
VKTX
)
62.32
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viking Thera
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Why Viking Therapeutics Stock Was So Healthy on Wednesday
September 25, 2024
Hardly for the first time, a pundit following the company waxed bullish on its future.
Via
The Motley Fool
Viking Therapeutics Unusual Options Activity For September 24
September 24, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?
September 23, 2024
Wall Street kicked off the week on a cautious note, with major indexes trading relatively flat as investors seek more clarity on the economic and political landscape.
Via
Benzinga
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
September 23, 2024
These two stocks could be rivals in the intense GLP-1 space in the future.
Via
The Motley Fool
What the Options Market Tells Us About Viking Therapeutics
September 17, 2024
Via
Benzinga
Viking Therapeutics Unusual Options Activity For September 11
September 11, 2024
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today
September 06, 2024
Via
Benzinga
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
September 20, 2024
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Via
The Motley Fool
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
September 20, 2024
Viking Therapeutics received an Overweight rating and a December 2025 price target of $80 from JPMorgan analysts.
Via
Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
September 19, 2024
Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.
Via
MarketBeat
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
September 18, 2024
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
Via
The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Via
The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Telemedicine once seemed like it was going to revolutionize healthcare.
Via
The Motley Fool
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
September 15, 2024
Terns Pharmaceuticals just proved that it's competitive in the weight loss field.
Via
The Motley Fool
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
September 13, 2024
The major indexes reclaimed key levels and many leaders flashed buy signals.
Via
Investor's Business Daily
These 2 Biotech Stocks Are Set to Soar
September 13, 2024
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.
Via
The Motley Fool
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
September 13, 2024
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.
Via
The Motley Fool
Why Investors Plowed Into Viking Therapeutics Stock Today
September 12, 2024
The company is looking especially good after some bad news coming from a rival.
Via
The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
September 12, 2024
An investment in these players today could score a big win down the road.
Via
The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
September 11, 2024
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.
Via
The Motley Fool
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
September 11, 2024
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.
Via
Benzinga
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
September 11, 2024
The company is working on a drug that targets GLP-1 and amylin to improve weight loss.
Via
Investor's Business Daily
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
September 07, 2024
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.
Via
The Motley Fool
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
September 05, 2024
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.
Via
Benzinga
Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year
September 05, 2024
Nvidia is heading for a 118% gain this year.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 03, 2024
Via
Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
September 03, 2024
This business has solid results in hand, lots of cash, and more catalysts coming.
Via
The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
August 29, 2024
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.
Via
Investor's Business Daily
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
August 29, 2024
Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.